KR20230124637A - 구조적으로 무질서한 서열에 대해 특이적인 항체 - Google Patents

구조적으로 무질서한 서열에 대해 특이적인 항체 Download PDF

Info

Publication number
KR20230124637A
KR20230124637A KR1020237024420A KR20237024420A KR20230124637A KR 20230124637 A KR20230124637 A KR 20230124637A KR 1020237024420 A KR1020237024420 A KR 1020237024420A KR 20237024420 A KR20237024420 A KR 20237024420A KR 20230124637 A KR20230124637 A KR 20230124637A
Authority
KR
South Korea
Prior art keywords
ala
ser
mab
seq
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024420A
Other languages
English (en)
Korean (ko)
Inventor
요나스 슐츠
울리 바인더
라스 프리드리히
미카엘라 제바우어
마르틴 스클랍스키
아르네 스케라
Original Assignee
엑스엘-프로테인 게엠베하
테크니쉐 우니베르지테트 뮌헨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스엘-프로테인 게엠베하, 테크니쉐 우니베르지테트 뮌헨 filed Critical 엑스엘-프로테인 게엠베하
Publication of KR20230124637A publication Critical patent/KR20230124637A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237024420A 2020-12-22 2021-12-22 구조적으로 무질서한 서열에 대해 특이적인 항체 Pending KR20230124637A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20216744.1 2020-12-22
EP20216744 2020-12-22
PCT/EP2021/087365 WO2022136582A1 (en) 2020-12-22 2021-12-22 Antibodies specific for structurally disordered sequences

Publications (1)

Publication Number Publication Date
KR20230124637A true KR20230124637A (ko) 2023-08-25

Family

ID=73856935

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024420A Pending KR20230124637A (ko) 2020-12-22 2021-12-22 구조적으로 무질서한 서열에 대해 특이적인 항체

Country Status (9)

Country Link
US (1) US20240294632A1 (https=)
EP (1) EP4267628A1 (https=)
JP (1) JP2024501316A (https=)
KR (1) KR20230124637A (https=)
CN (1) CN117120476A (https=)
AU (1) AU2021405029A1 (https=)
CA (1) CA3200238A1 (https=)
IL (1) IL303816A (https=)
WO (1) WO2022136582A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118146384A (zh) * 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
EP4602053A2 (en) * 2022-10-14 2025-08-20 Aikium Inc. Protein scaffolds for disordered regions
WO2025088192A1 (en) * 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
CN117683866B (zh) * 2024-01-22 2024-08-06 湛江中心人民医院 检测细胞中dna的方法
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物

Also Published As

Publication number Publication date
WO2022136582A1 (en) 2022-06-30
JP2024501316A (ja) 2024-01-11
EP4267628A1 (en) 2023-11-01
AU2021405029A9 (en) 2025-03-13
AU2021405029A1 (en) 2023-07-20
US20240294632A1 (en) 2024-09-05
CA3200238A1 (en) 2022-06-30
CN117120476A (zh) 2023-11-24
IL303816A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US11242388B2 (en) ROR1 antibody compositions and related methods
KR20230124637A (ko) 구조적으로 무질서한 서열에 대해 특이적인 항체
CN108884160B (zh) 抗ror1抗体
US12275789B2 (en) Human antibodies binding to ROR2
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
KR102355310B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
KR102355309B1 (ko) 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
JP7798805B2 (ja) 抗ＴＧＦβ抗体及びその治療的使用
KR20240033183A (ko) 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
EP2861622A2 (en) Anti-cd22 anti-idiotypic antibodies and uses thereof
JP7419238B2 (ja) Ｐｄ１結合剤
KR20240122885A (ko) 항b7-h7 항체 또는 이의 항원 결합 단편 및 제조 방법과 응용
CN117285627A (zh) 抗ccr8抗体及其用途
Schilz et al. Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope
CN120077069A (zh) 趋化因子受体8（ccr8）抗体
US20250019457A1 (en) Trop2 antibodies
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
JP2025508603A (ja) ネコ抗体ライブラリー
US20090155850A1 (en) Horse:Human Chimeric Antibodies
CN119080939A (zh) 单克隆抗体及其在制备检测喜树碱类化合物与蛋白复合物的试剂中的应用
CN121609799A (zh) 一种抗pd-l1的纳米抗体、含其的双特异性重组蛋白及其应用
CN120239709A (zh) 抗体、其抗原结合片段及其药物用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241206

Comment text: Request for Examination of Application